Clinical trialCLINICALTRIALSMar 26
New Clinical Trial: Dose Escalation Study of CLR 131 in Pediatric Relapsed/Refractory Malignant Tumors Including Neuroblastoma and Sarcomas (NCT03478462)
Researchers are testing a new cancer drug called CLR 131 in children and young adults whose cancers have come back or stopped responding to standard treatments. The study includes kids with several types of hard-to-treat cancers like neuroblastoma, sarcomas, and brain tumors. This is an early-stage study to figure out the right dose and see if the drug is safe and effective.
WHY IT MATTERSThis trial offers a potential treatment option for children with relapsed or refractory neuroblastoma, sarcomas, and other pediatric solid tumors where standard treatments have failed—conditions with very limited curative options.